Need to keep on prime of the science and politics driving biotech immediately? Join to get our biotech e-newsletter in your inbox.
Good day, all. Damian right here with an replace on the plight of the different Covid-19 vaccine firm, Wall Avenue’s newest GLP-1 commerce, and the hunt for a common antivenom.
The necessity-to-know this morning
- Ocular Therapeutics introduced a shakeup of its senior administration staff and a $325 million non-public placement.
- Amylyx Therapeutics stated outcomes from a carefully adopted Part 3 research of its therapy for ALS might come before the start of the second quarter — sooner than beforehand anticipated.
- Moderna earnings are here.
Novavax’s cash goes within the flawed route
The excellent news for Novavax is that it’s now not dealing with a $700 million dispute with a worldwide charity group. The unhealthy information is that settling that dispute will pressure the struggling firm to pay out $400 million over the following 5 years.
Get limitless entry to award-winning journalism and unique occasions.
Subscribe
